文献速递临床试验与 GCP

INVENT COVID试验:一项研究静脉注射甲磺酸伊马替尼(Impentri®)治疗COVID-19所致急性呼吸窘迫综合征受试者有效性与安全性的随机对照试验结构化方案

The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19.
PubMed 文献 · Trials · 2022-02-16

本研究为随机、双盲、平行分组、安慰剂对照、多中心临床试验,计划纳入90例接受机械通气的COVID-19所致中度至重度急性呼吸窘迫综合征(ARDS)成年受试者,1:1随机接受静脉注射甲磺酸伊马替尼200 mg每日两次或安慰剂,持续7天或至ICU出院或死亡。主要结局为第1天至第4天血管外肺水指数(EVLWi)的变化,次要结局包括氧合与通气参数、有创机械通气时长、28天内无呼吸机天数、ICU住院时长、28天死亡率及安全性、耐受性和药代动力学。

要点

  • 纳入90例机械通气的COVID-19所致中重度ARDS成年受试者,1:1随机分组。
  • 干预为静脉注射甲磺酸伊马替尼200 mg每日两次或安慰剂,持续7天。
  • 主要结局为第1天至第4天EVLWi变化,次要结局包括28天死亡率等。

核心结论

  • 研究旨在探讨静脉注射伊马替尼在机械通气的COVID-19相关ARDS受试者中的有效性与安全性。
  • 作者假设伊马替尼可减轻肺水肿(以PiCCO导管测量的血管外肺水评估),从而逆转低氧性呼吸衰竭并加速恢复。
  • 作者进一步假设伊马替尼可降低疾病严重程度,反映为28天死亡率、机械通气时长和ICU住院时长的降低。

研究设计与样本

  • 随机、双盲、平行分组、安慰剂对照、多中心临床试验。
  • 计划纳入90例18岁及以上、因机械通气入住ICU、符合柏林标准的中重度ARDS且SARS-CoV2聚合酶链反应检测阳性的受试者。
  • 受试者按1:1比例随机接受甲磺酸伊马替尼200 mg每日两次或安慰剂静脉输注,持续7天,或至ICU出院或死亡。
  • 主要结局为第1天至第4天血管外肺水指数(EVLWi)的变化。
  • 次要结局包括氧合与通气参数变化、有创机械通气时长、28天研究期内无呼吸机天数、ICU住院时长、随机化后28天死亡率,以及安全性、耐受性和药代动力学。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The coronavirus disease 2019 (COVID-19) pandemic has led to a disruptive increase in the number of intensive care unit (ICU) admissions with acute respiratory distress syndrome (ARDS). ARDS is a severe, life-threatening medical condition characterized by widespread inflammation and vascular leak in the lungs. Although there is no proven therapy to reduce pulmonary vascular leak in ARDS, recent studies demonstrated that the tyrosine kinase inhibitor imatinib reinforces the endothelial barrier and prevents vascular leak in inflammatory conditions, while leaving the immune response intact. METHODS: This is a randomized, double-blind, parallel-group, placebo-controlled, multicenter clinical trial of intravenous (IV) imatinib mesylate in 90 mechanically ventilated subjects with COVID-19-induced ARDS. Subjects are 18 years or older, admitted to the ICU for mechanical ventilation, meeting the Berlin criteria for moderate-severe ARDS with a positive polymerase chain reaction test for SARS-CoV2. Participants will be randomized in a 1:1 ratio to either imatinib (as mesylate) 200 mg bis in die (b.i.d.) or placebo IV infusion for 7 days, or until ICU discharge or death. The primary study outcome is the change in Extravascular Lung Water Index (EVLWi) between day 1 and day 4. Secondary outcome parameters include changes in oxygenation and ventilation parameters, duration of invasive mechanical ventilation, number of ventilator-free days during the 28-day study period, length of ICU stay, and mortality during 28 days after randomization. Additional secondary parameters include safety, tolerability, and pharmacokinetics. DISCUSSION: The current study aims to investigate the efficacy and safety of IV imatinib in mechanically ventilated subjects with COVID-19-related ARDS. We hypothesize that imatinib decreases pulmonary edema, as measured by extravascular lung water using a PiCCO catheter. The reduction in pulmonary edema may reverse hypoxemic respiratory failure and hasten recovery. As pulmonary edema is an important contributor to ARDS, we further hypothesize that imatinib reduces disease severity, reflected by a reduction in 28-day mortality, duration of mechanical ventilation, and ICU length of stay. TRIAL STATUS: Protocol version and date: V3.1, 16 April 2021. Recruitment started on 09 March 2021. Estimated recruitment period of approximately 40 weeks. TRIAL REGISTRATION: ClinicalTrials.gov NCT04794088 . Registered on 11 March 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Atmowihardjo L, Schippers JR, Bartelink IH, et al. The INVENT COVID trial: a structured protocol for a randomized controlled trial investigating the efficacy and safety of intravenous imatinib mesylate (Impentri®) in subjects with acute respiratory distress syndrome induced by COVID-19. Trials. 2022. PMID: 35172891. doi:10.1186/s13063-022-06055-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。